Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.92 USD
Change Today -0.01 / -0.52%
Volume 237.7K
DRRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

durect corporation (DRRX) Snapshot

Open
$1.92
Previous Close
$1.93
Day High
$1.92
Day Low
$1.89
52 Week High
03/30/15 - $2.05
52 Week Low
10/27/14 - $0.68
Market Cap
218.4M
Average Volume 10 Days
529.6K
EPS TTM
$-0.19
Shares Outstanding
113.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DURECT CORPORATION (DRRX)

durect corporation (DRRX) Related Businessweek News

No Related Businessweek News Found

durect corporation (DRRX) Details

DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. It provides ALZET product line comprising osmotic pumps and accessories that are used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers, which are used as raw materials for pharmaceutical and medical device under the LACTEL brand. It also focuses on developing products for various chronic and episodic, or acute medical conditions, including pain, central nervous system disorders, metabolic disorders, cardiovascular disease, ophthalmic disorders, and other diseases. The company develops REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a transdermal bupivacaine for the treatment of pain associated with post-herpetic neuralgia; and Relday, a risperidone product to treat the symptoms of schizophrenia and bipolar I disorder in adults and teenagers. It also develops ORADUR-ADHD, a drug candidate for the treatment of attention deficit hyperactivity disorder; ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials to treat chronic pain, and oxymorphone; and DUR-928, an endogenous small molecule for the treatment of acute organ injuries and metabolic/lipid disorders. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd., Impax Laboratories, Inc., Zogenix, Inc., Pain Therapeutics, Inc., and Hospira, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

102 Employees
Last Reported Date: 03/3/15
Founded in 1998

durect corporation (DRRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $450.7K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $248.2K
Chief Financial Officer
Total Annual Compensation: $310.5K
Executive Vice President of Pharmaceutical Sy...
Total Annual Compensation: $298.2K
Compensation as of Fiscal Year 2013.

durect corporation (DRRX) Key Developments

DURECT Corporation Announces Initiation of DUR-928 Multi-Dose Phase 1 Study

DURECT Corporation announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury. Phase 1 Multi-Dose Study: This Phase 1 trial is a single-site, randomized, double-blinded, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of DUR-928 when orally administered once daily for 5 consecutive days to healthy volunteers. The 20-subject study will evaluate DUR-928 in 2 consecutive 10-subject cohorts, the first receiving DUR-928 at a lower dose and the second at a higher dose. DUR-928 is an endogenous, orally bioavailable small molecule that modulates the activity of several nuclear receptors that play an important regulatory role in lipid homeostasis, inflammation, and cell survival. A systems biology study involving over 23,000 genes showed that DUR-928 modulates the activity of more than 240 genes, including ACC, FAS, HMGR, Cyp7A1, LXR, PPAR?, NF?B/I?B, TNFa, IL-1a, IL-6, COX-2, PCSK9, and others. The biological activity of DUR-928 has been demonstrated in 6 different animal disease models, 3 representing acute toxic or ischemic organ injury (kidney and liver) and 3 representing chronic disorders of hepatic lipid accumulation and dysfunction (NAFLD/NASH). Animal pharmacokinetics and toxicity studies have shown DUR-928 to be orally bioavailable and safe at all doses tested to date. An injectable formulation, envisioned for use in acute conditions, is currently undergoing animal testing.

DURECT Corporation Announces Successful Completion of Phase 1 Study on Potential Liver Disease and Steatohepatitis Treatment

DURECT Corporation announced that a Phase 1 clinical trial on DUR-928 was completed successfully, noting that the drug was well-tolerated at all dose levels, with no treatment-related adverse events reported and no subjects withdrawing from the study. DUR-928 is a new chemical entity (NCE) that may have broad applicability as a treatment of metabolic diseases such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and in acute organ injuries such as acute kidney injury.

DURECT Corporation Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

DURECT Corporation reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $4.269 million compared to $4.289 million for the same period a year ago. Loss from operations was $5.355 million compared to $5.092 million for the same period a year ago. Net loss was $5.940 million or $0.05 per diluted share compared to $5.1 million or $0.05 per diluted share for the same period a year ago. For the year, the company reported total revenues of $19.401 million compared to $15.326 million for the same period a year ago. Loss from operations was $20.998 million compared to $21.162 million for the same period a year ago. Net loss was $22.110 million or $0.20 per diluted share compared to $21.452 million or $0.21 per diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRX:US $1.92 USD -0.01

DRRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Egalet Corp $11.03 USD -0.36
Elite Pharmaceuticals Inc $0.25 USD -0.0039
Supernus Pharmaceuticals Inc $13.47 USD -0.02
Veloxis Pharmaceuticals A/S kr0.89 DKK 0.00
Zogenix Inc $1.58 USD -0.02
View Industry Companies
 

Industry Analysis

DRRX

Industry Average

Valuation DRRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DURECT CORPORATION, please visit www.durect.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.